Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Pa­tients tak­ing Take­da’s En­tyvio for Crohn’s dis­ease will now have the op­tion of a sub­cu­ta­neous ver­sion.

Take­da an­nounced the la­bel ex­pan­sion on Fri­day, sev­er­al months af­ter win­ning a first ap­proval for the sub­cu­ta­neous for­mu­la­tion in ul­cer­a­tive col­i­tis. En­tyvio, or vedolizum­ab, was orig­i­nal­ly ap­proved as an in­tra­venous drug in 2014 and ad­min­is­tered via a rough­ly 30-minute-long in­fu­sion.

The new for­mu­la­tion is tak­en as a main­te­nance ther­a­py fol­low­ing in­duc­tion with IV En­tyvio. It’s a sin­gle-dose, pre­filled pen, to be self-ad­min­is­tered “at home or on the go,” Take­da’s US gas­troen­terol­o­gy busi­ness unit head Bran­don Monk said in a news re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER